Aquestive Therapeutics, Inc. AQST Ex-United States — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s ex-united states — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s ex-united states — revenue?
- Aquestive Therapeutics, Inc. (AQST) reported ex-united states — revenue of $1.2M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s ex-united states — revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s ex-united states — revenue decreased by 65.9% year-over-year, from $3.52M to $1.2M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s ex-united states — revenue?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s ex-united states — revenue has grown at a 17.0% compound annual growth rate (CAGR), from $7.97M to $14.94M.
- What does ex-united states — revenue mean?
- This metric represents the total gross revenue generated by the company from pharmaceutical product sales and licensing activities conducted outside of the United States. It reflects the company's international market penetration and the success of its commercialization strategy in foreign jurisdictions. Monitoring this figure helps investors assess the geographic diversification of the company's revenue streams and its ability to navigate global regulatory and distribution landscapes.